LOF PARTNERS LLC 4

Accession 0001181431-13-010399

CIK 0000810084other

View on SEC.gov Company Profile

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 12:24 PM ET

Size

28.9 KB

Accession

0001181431-13-010399

Insider Transaction Report

Form 4

Period: 2007-06-01

BIOJECT MEDICAL TECHNOLOGIES INCBJCT

LIFE SCIENCES OPPORTUNITIES FUND II LP

10% Owner

Transactions

Other
Series E Convertible Preferred Stock
2007-06-01+22,328→ 301,425 total
Exercise: $1.37From: 2007-06-01→ Common Stock (22,328 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+24,114→ 325,539 total
Exercise: $1.37From: 2008-06-01→ Common Stock (24,114 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+15,352→ 207,255 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (15,352 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+124,720→ 1,683,725 total
Exercise: $1.37From: 2007-06-01→ Common Stock (124,720 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+14,215→ 191,903 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $137.00From: 2007-06-01→ Common Stock (14,215 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+134,698→ 1,818,423 total
Exercise: $1.37From: 2008-06-01→ Common Stock (134,698 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+45,104→ 559,076 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2007-06-01→ Common Stock (45,104 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+48,615→ 607,691 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (48,615 underlying)

SMH CAPITAL INC.

10% OwnerOther

Transactions

Other
Series E Convertible Preferred Stock
2008-06-01+24,114→ 325,539 total
Exercise: $1.37From: 2008-06-01→ Common Stock (24,114 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+14,215→ 191,903 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $137.00From: 2007-06-01→ Common Stock (14,215 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+124,720→ 1,683,725 total
Exercise: $1.37From: 2007-06-01→ Common Stock (124,720 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+134,698→ 1,818,423 total
Exercise: $1.37From: 2008-06-01→ Common Stock (134,698 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+15,352→ 207,255 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (15,352 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+22,328→ 301,425 total
Exercise: $1.37From: 2007-06-01→ Common Stock (22,328 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+45,104→ 559,076 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2007-06-01→ Common Stock (45,104 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+48,615→ 607,691 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (48,615 underlying)

LOF PARTNERS LLC

Other

Transactions

Other
Series E Convertible Preferred Stock
2007-06-01+124,720→ 1,683,725 total
Exercise: $1.37From: 2007-06-01→ Common Stock (124,720 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+22,328→ 301,425 total
Exercise: $1.37From: 2007-06-01→ Common Stock (22,328 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+48,615→ 607,691 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (48,615 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+14,215→ 191,903 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $137.00From: 2007-06-01→ Common Stock (14,215 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+15,352→ 207,255 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (15,352 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+24,114→ 325,539 total
Exercise: $1.37From: 2008-06-01→ Common Stock (24,114 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+134,698→ 1,818,423 total
Exercise: $1.37From: 2008-06-01→ Common Stock (134,698 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+45,104→ 559,076 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2007-06-01→ Common Stock (45,104 underlying)

GALE JAMES C

Director

Transactions

Other
Series E Convertible Preferred Stock
2008-06-01+24,114→ 325,539 total
Exercise: $1.37From: 2008-06-01→ Common Stock (24,114 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+45,104→ 559,076 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2007-06-01→ Common Stock (45,104 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+22,328→ 301,425 total
Exercise: $1.37From: 2007-06-01→ Common Stock (22,328 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+124,720→ 1,683,725 total
Exercise: $1.37From: 2007-06-01→ Common Stock (124,720 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+15,352→ 207,255 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (15,352 underlying)
Other
Series E Convertible Preferred Stock
2007-06-01+14,215→ 191,903 total(indirect: By Sanders Opportunity Fund, L.P.)
Exercise: $137.00From: 2007-06-01→ Common Stock (14,215 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+48,615→ 607,691 total(indirect: By Sanders Opportunity Fund (Institutional), L.P.)
Exercise: $1.37From: 2008-06-01→ Common Stock (48,615 underlying)
Other
Series E Convertible Preferred Stock
2008-06-01+134,698→ 1,818,423 total
Exercise: $1.37From: 2008-06-01→ Common Stock (134,698 underlying)

Footnotes (5)

[F1]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II, L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC (as assignee of Sanders Morris Harris Inc. ), the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial ownnership of the reported securities except to the extent of their pecuniary interest therein.
[F2]These securities are owned directly by Life Sciences Opportunities Fund II (Institutional), L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II (Institutional), L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC (as assignee of Sanders Morris Harris Inc.), the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
[F3]These securities are owned directly by Sanders Opportunity Fund (Institutional), L.P. and indirectly by SMW Investments I, LLC, the controlling member of SOF Management, LLC., the general partner of Sanders Opportunity Fund (Institutional), L.P. SMW Investments I, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
[F4]These securities are owned directly by Sanders Opportunity Fund, L.P. and indirectly by SMW Investments I, LLC, the controlling member of SOF Management, LLC., the general partner of Sanders Opportunity Fund, L.P. SMW Investments I, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
[F5]Shares of Series E 8% Cumulative Convertible Preferred Stock issued as a stock dividend pursuant to the terms of a Securities Purchase Agreement dated as of March 8, 2006, and are convertible into shares of common stock one a one-for-one basis. The Series E Preferred Stock bear dividends for the first two years following issuance at the rate of 8% payable in additional shares of Series E Preferred Stock.

Documents

1 file

4
rrd370836.xmlPrimary

Issuer

BIOJECT MEDICAL TECHNOLOGIES INC

CIK 0000810084

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001280952

Filing Metadata

Form type: 4
Filed: Feb 18, 7:00 PM ET
Accepted: Feb 19, 12:24 PM ET
Size: 28.9 KB

View on SEC.gov